JP2018516931A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516931A5
JP2018516931A5 JP2017562660A JP2017562660A JP2018516931A5 JP 2018516931 A5 JP2018516931 A5 JP 2018516931A5 JP 2017562660 A JP2017562660 A JP 2017562660A JP 2017562660 A JP2017562660 A JP 2017562660A JP 2018516931 A5 JP2018516931 A5 JP 2018516931A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
binding antibody
administered
functional fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017562660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516931A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/053242 external-priority patent/WO2016193931A1/en
Publication of JP2018516931A publication Critical patent/JP2018516931A/ja
Publication of JP2018516931A5 publication Critical patent/JP2018516931A5/ja
Pending legal-status Critical Current

Links

JP2017562660A 2015-06-04 2016-06-02 末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用 Pending JP2018516931A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562170761P 2015-06-04 2015-06-04
US62/170,761 2015-06-04
PCT/IB2016/053242 WO2016193931A1 (en) 2015-06-04 2016-06-02 Use of il-1 beta binding antibodies to treat peripheral arterial disease

Publications (2)

Publication Number Publication Date
JP2018516931A JP2018516931A (ja) 2018-06-28
JP2018516931A5 true JP2018516931A5 (https=) 2018-08-16

Family

ID=56132984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017562660A Pending JP2018516931A (ja) 2015-06-04 2016-06-02 末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用

Country Status (6)

Country Link
US (2) US20210198356A1 (https=)
EP (1) EP3303388A1 (https=)
JP (1) JP2018516931A (https=)
AU (1) AU2016272900A1 (https=)
CA (1) CA2988055A1 (https=)
WO (1) WO2016193931A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2575853A (en) * 2018-07-25 2020-01-29 Robert Wotherspoon Hugh IL-1ß binding antibody
US12110299B2 (en) 2018-09-17 2024-10-08 Yungjin Pharm. Co., Ltd. Thiazole derivatives and pharmaceutically acceptable salts thereof
BR112021011351A2 (pt) * 2018-12-21 2021-11-16 Novartis Ag Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
AU2013344796B2 (en) 2012-11-16 2016-11-10 Novartis Ag Use of IL-1 beta binding antibodies for treating peripheral arterial disease

Similar Documents

Publication Publication Date Title
EP1696900B1 (en) Use of treprostinil to treat ischemic lesions
Dahlöf et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension)
KR101186029B1 (ko) 신경병증성 당뇨병성 족부 궤양을 치료하기 위한트레프로스티닐의 용도
JP2015187125A5 (https=)
IL277127B1 (en) Using pcsk9 tracking to reduce cardiovascular risk
JP2016502526A5 (https=)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2017528427A5 (https=)
JP2017132791A (ja) 組み合わせ組成物
JP2021527128A5 (https=)
JP2021527129A5 (https=)
JP2018531605A5 (https=)
RU2008135360A (ru) Композиции и способы лечения пациентов с сердечно-сосудистыми, церебрально-васкулярными и другими сосудистыми заболеваниями
JP2018516931A5 (https=)
WO2022039619A1 (ru) Противовирусное средство для комбинированной терапии covid-19 (sars-cov-2)
RU2523412C1 (ru) Способ лечения больных облитерирующими заболеваниям и артерий нижних конечностей
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
JPWO2019237053A5 (https=)
JPWO2019237054A5 (https=)
Hall et al. Vitamin B12 and coordination exercises for combined degeneration of the spinal cord in pernicious anemia
KR20230043905A (ko) 5-메틸-1,2,4-옥사디아졸-3-일 화합물의 저용량 요법 및 제제
Henderson et al. Chronic inflammatory demyelinating polyradiculoneuropathy and severe peripheral oedema: a renal explanation
RU2025131205A (ru) Производные имидазотриазина в качестве модуляторов il-17
RU2025131206A (ru) Производные имидазотриазина в качестве модуляторов il-17
Jones et al. A comparison of the efficacy and tolerability of the PCSK9 inhibitors, alirocumab and evolocumab, in routine lipid clinic practice